Provided by Tiger Trade Technology Pte. Ltd.

InMed Pharmaceuticals Inc

1.46
-0.1200-7.59%
Post-market: 1.460.00000.00%17:48 EDT
Volume:71.61K
Turnover:107.41K
Market Cap:7.80M
PE:-0.58
High:1.62
Open:1.58
Low:1.45
Close:1.58
52wk High:2.50
52wk Low:0.5750
Shares:5.34M
Float Shares:1.93M
Volume Ratio:0.67
T/O Rate:3.71%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.5324
EPS(LYR):-8.3630
ROE:-112.65%
ROA:-54.61%
PB:1.13
PE(LYR):-0.17

Loading ...

NASDAQ TRADE HALT HALT NEWS PENDING AT 07:55 AM

Reuters
·
May 19

InMed net loss widens 40% to USD 2.97 million in Q3 FY26

Reuters
·
May 07

FOCUS-Companies with cannabis-based drugs eye IPOs, private funding boost after US reclassification

Reuters
·
Apr 30

InMed Pharmaceuticals files prospectus supplement for at-the-market common share offering

Reuters
·
Apr 04

InMed receives Nasdaq notification regarding minimum bid price compliance

TIPRANKS
·
Mar 30

InMed Pharmaceuticals drops on Nasdaq notice; bid price stays below $1.00 for 30 straight sessions

Reuters
·
Mar 28

InMed Pharmaceuticals announces preclinical data on effects of INM-901

TIPRANKS
·
Mar 23

InMed Pharmaceuticals Inc - Announces Positive Data Supporting Inm-901 Alzheimer's Program - SEC Filing

THOMSON REUTERS
·
Mar 23

InMed Pharmaceuticals Inc - Targets Ind Submission and Phase 1 Clinical Trial for Inm-901 in 2027 - SEC Filing

THOMSON REUTERS
·
Mar 23

InMed reports INM-901 reduces IL-6 and IL-8 in human Alzheimer’s brain organoid models

Reuters
·
Mar 23

InMed Pharmaceuticals files $50M mixed securities shelf

TIPRANKS
·
Mar 21

InMed Pharmaceuticals provides development outlook for 2026

TIPRANKS
·
Mar 09

InMed targets 2027 Phase 1 trial start for INM-901 and plans FDA pre-IND meeting in Q3 2026

Reuters
·
Mar 09

InMed winds down BayMedica commercial operations to focus on drug development pipeline

Reuters
·
Mar 07

BRIEF-InMed Pharmaceuticals Inc - On March 4, Co Confirmed And Approved The Decision To Wind Down Baymedica's Commercial Operations - SEC Filing

Reuters
·
Mar 07

InMed Pharmaceuticals Inc - on March 4, Co Confirmed and Approved the Decision to Wind Down Baymedica's Commercial Operations - SEC Filing

THOMSON REUTERS
·
Mar 07

InMed pro forma net loss widens 18% to $8.83 million for FY2025

Reuters
·
Mar 07